RSV
BD Veritor™ Plus System
Respiratory Syncytial Virus (RSV) rapid antigen testing
Effectively test for RSV
Viral respiratory tract infections are responsible for widespread disease.¹ Respiratory syncytial virus (RSV) is a leading cause of lower respiratory tract infections (LRI) in young children in both the developed and developing worlds²⁻³.
BD Veritor™ Plus System for RSV
The BD Veritor™ Plus System for Rapid Detection of RSV is a digital immunoassay (DIA) that qualitatively detects RSV fusion protein. There are two test kits available: the CLIA-waived test kit detects RSV fusion protein in infants and pediatric patients under the age of 6 years suspected of having RSV by their healthcare provider; the laboratory kit detects RSV fusion protein in patients up to 20 years of age who are suspected of having RSV by their healthcare provider.
The system offers one-button functionality for workflow flexibility, allowing health care providers to confidently use the Analyzer.
Fast, reliable results in as few as 11 minutes⁴⁻⁵
Two analysis options to optimize workflow
Rapid RSV test clinical performance data
RSV is a common virus, and can spread rapidly, especially among children²⁻³.
Comparison of BD Veritor™ System for Rapid Detection of RSV Test to viral cell culture.
In the chart below, data shows that, when compared to an accepted standard method, the BD Veritor™ System has a high Sensitivity rate (sensitivity measures the ability of the test to appropriately make a positive identification) and fewer false negatives⁴⁻⁵. In addition, data shows a high Specificity rate (specificity measures the ability of the test to properly identify the absence of the test target) and fewer false positives⁴⁻⁵.
Specimen Type: Nasopharyngeal Swab (NPS)⁴⁻⁵
88.4%
Sensitivity
(95% C.I 82.8-92.4%)
98.3%
Specificity
(95% C.I 96.8-99.7%)
Reference method : Viral Cell Culture
Sensitiivity : 88.4% (95% CI: 82.8-92.4%)
Specificity : 98.3% (95% CI: 96.8-99.1%)
Specimen Type: Nasal Wash
(NPWA)⁴⁻⁵
91.6%
Sensitivity
(95% C.I 86.3-94.9%)
94.5%
Specificity
(95% C.I 91.2-96.7%)
Reference method : Viral Cell Culture
Sensitiivity : 91.6% (95% C.I 86.3-94.9%)
Specificity : 94.5% (95% C.I 91.2-96.7%)
Summary of the performance of the BD Veritor™ System for Rapid Detection of RSV Test compared to viral cell culture by specimen type, all sites
NPS
VIRAL CELL CULTURE
BD Veritor TM
| P | N | Total | |
|---|---|---|---|
| P | 153 | 9 | 162 |
| N | 20 | 524 | 544 |
| Total | 173 | 533 | 706 |
NPWA
VIRAL CELL CULTURE
BD Veritor TM
| P | N | Total | |
|---|---|---|---|
| P | 152 | 15 | 167 |
| N | 14 | 259 | 273 |
| Total | 166 | 274 | 440 |
Explanation of Terms:
Sensitivity: Ability of the test to properly identify the test target when it is present, compared to an accepted standard method (viral culture).
Specificity: Ability of the test to properly identify when the test target is not present, compared to an accepted standard method (viral culture).
P: Positive
N: Negative
C.I.: Confidence Interval
Performance characteristics for the BD Veritor™ System for Rapid Detection of RSV test were established in multi-center clinical studies conducted at five U.S. trial sites during the 2011–2012 respiratory season. A total of 1174 prospectively collected specimens received in the laboratory with an order for respiratory virus testing were enrolled in the study, of which, 26 were noncompliant with the study protocol and one was noncompliant on the viral cell culture reference testing level. Removal of these specimens yields a total of 1147 specimens. One additional specimen had a final undetermined viral cell culture reference result which could not be verified. Removal of this specimen results in a total of 1146 specimens. A total of 1146 were evaluated using the BD Veritor™ System for Rapid Detection of RSV test and viral cell culture. The prospective specimens consisted of 440 NPWA and 706 NPS in transport media from symptomatic patients. 44.3% of the samples were from females and 55.7% from males. 80% of patients were 2 years and under.
The performance of the BD Veritor™ System for Rapid Detection of RSV test was compared to an FDA cleared D³ Duet™ DFA on R-Mix cell culture and is presented in the above table.
BD Veritor™ Plus System ordering and reimbursement
As your facility continues to provide valuable rapid diagnostic testing, you may need to reorder. Please click here for more information.
REFERENCES
- Vaccine Knowledge Project: http://vk.ovg.ox.ac.uk/rsv. Accessed December 19, 2018
- Nair, Harish et. al. Global burden of acute lower respiratory infections due to respiratory syncytial virus in young children: a systematic review and meta-analysis. Lancet. 2010 May 1;375(9725):1500-2
- CDC: https://www.cdc.gov/rsv/about/symptoms.html
- BD Veritor System for Rapid Detection of Respiratory Syncytial Virus (RSV), CLIA-waived kit[ package insert], 8086098. Franklin Lakes, NJ: Becton, Dickinson and Company.
- BD Veritor System for Rapid Detection of Respiratory Syncytial Virus (RSV),laboratory kit [ package in-sert], 8086100. Franklin Lakes, NJ: Becton, Dickinson and Company.
Resources
Contact Us
To request a demo or for more information on our products contact our Sales Representatives
Contact UsSupport
For training, equipment servicing and more, contact our Customer Success team
Contact Support